Sight Sciences (NASDAQ:SGHT) vs. CardioGenics (OTCMKTS:CGNH) Financial Contrast

CardioGenics (OTCMKTS:CGNH) and Sight Sciences (NASDAQ:SGHT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Risk and Volatility

CardioGenics has a beta of 2.54, suggesting that its stock price is 154% more volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.42, suggesting that its stock price is 142% more volatile than the S&P 500.

Profitability

This table compares CardioGenics and Sight Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CardioGenics	N/A	N/A	N/A
Sight Sciences	-60.63%	-61.59%	-36.11%

Analyst Ratings

This is a summary of recent ratings and target prices for CardioGenics and Sight Sciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CardioGenics	0	0	0	0	0.00
Sight Sciences	1	3	4	0	2.38

Sight Sciences has a consensus price target of $8.30, suggesting a potential upside of 15.60%. Given Sight Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe Sight Sciences is more favorable than CardioGenics.

Valuation and Earnings

This table compares CardioGenics and Sight Sciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CardioGenics	N/A	N/A	N/A	N/A	N/A
Sight Sciences	$79.87 million	4.75	-$51.51 million	($0.90)	-7.98

CardioGenics has higher earnings, but lower revenue than Sight Sciences.

Institutional and Insider Ownership

55.5% of Sight Sciences shares are held by institutional investors. 41.4% of CardioGenics shares are held by company insiders. Comparatively, 30.9% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

About CardioGenics

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.

About Sight Sciences

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.